334708-05-3

Usage

Uses

Used in Pharmaceutical Industry:
2-Hydroxy-5-sulfopyridine-3-carboxylic acid is used as a building block in the synthesis of complex molecules for pharmaceutical applications. Its hydroxyl and sulfonic acid groups enable the formation of various chemical bonds and interactions, making it a valuable component in the development of new drugs.
Used in Agrochemical Industry:
In the agrochemical industry, 2-Hydroxy-5-sulfopyridine-3-carboxylic acid serves as a key intermediate in the production of agrochemicals. Its unique properties allow it to be incorporated into the synthesis of pesticides, herbicides, and other agricultural chemicals, enhancing their effectiveness and selectivity.
Used in Organic Synthesis:
2-Hydroxy-5-sulfopyridine-3-carboxylic acid is used as a versatile reagent in organic synthesis. Its functional groups facilitate various chemical reactions, such as esterification, amidation, and condensation, making it a valuable tool for the synthesis of a wide range of organic compounds.
Used as a Chelating Agent in Metal Coordination:
2-Hydroxy-5-sulfopyridine-3-carboxylic acid is utilized as a chelating agent in metal coordination chemistry. Its ability to form stable complexes with metal ions makes it suitable for applications in catalysis, analytical chemistry, and the development of new materials with unique properties.
Used in Dye and Pigment Production:
In the dye and pigment industry, 2-Hydroxy-5-sulfopyridine-3-carboxylic acid is used as a key component in the synthesis of various dyes and pigments. Its chemical structure allows for the creation of a wide range of colors and shades, making it an essential ingredient in the production of high-quality dyes and pigments.
Used in Corrosion Inhibitor Production:
2-Hydroxy-5-sulfopyridine-3-carboxylic acid is employed in the production of corrosion inhibitors. Its ability to form stable complexes with metal surfaces helps protect them from corrosion, making it a valuable additive in various industrial applications, such as in the manufacturing of coatings, paints, and other protective materials.

Upstream product

• 609-71-2 2-hydroxy-3-carboxypyridine 

Downstream Products

• 247582-73-6 2-Ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridine-3-carboxylic Acid 
• 4027-59-2 3-Ethyl-1H-pyrazole-5-carboxylic Acid 

Relevant academic research and scientific papers

Therapeutic agents

The invention relates anhydrous para-toluenesulphonic acid salts of 3-ethyl-5-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-(2-methoxyethoxy) pyridin-3-yl]-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo [4,3-d]pyrimidin-7-one having the formula (I): a process for

Novel process for the preparation of pyrazolopyrimidinones

There is provided a process for the production a compound of general formula I: wherein A, R1, R2, R3 and R4 have meanings given in the description, which process comprises the reaction of a compound of formula II, wherein Rx is a group substitutable by an aminopyrazole, with a compound of general formula III

Novel process for the preparation of pyrazolopyrimidinones

There is provided a process for the production a compound of general formula I: 1wherein A, R1, R2, R3 and R4 have meanings given in the description, which process comprises the dehydrogenation of a compound of general formula II, 2

Crystalline therapeutic agent

A polymorph of 1-{6-ethoxy-5-[3-ethyl-6,7-dihydro-2-(2-methoxyethyl)-7-oxo-2H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-pyridylsulfonyl}-4-ethylpiperazine.

Pyrazolopyrimidine derivatives

The present invention provides a compound of formula (I): where Q is a group of formula: These compounds inhibit cyclic guanosine 3',5'-monophosphate phosphodiesterases (cGMP PDEs). More notably, the compounds are potent and selective inhibitors of the type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases and have utility therefore in a variety of therapeutic areas. In particular, the present compounds are of value for the curative or prophylactic treatment of mammalian sexual disorders.

The process development of a scaleable route to the PDE5 inhibitor UK-357,903

A case history is outlined for the development of a scaleable route to the drug candidate UK-357,903. Despite the partial structural similarities to those of sildenafil (Viagra), the introduction of the central pyridine moiety within UK-357,903 had a significant impact on the commercial process. In particular, the triply activated 2-alkoxypyridyl moiety of UK-357,903 is much more susceptible to nucleophilic attack than the 2-ethoxyphenyl moiety of sildenafil, necessitating the development of new chemistry. Particular items of note are (i) the new six-step route to the advanced 2-ethoxy-5-(4-ethylpiperazinylsulfonyl)nicotinic acid intermediate and the subsequent telescoping to a two-pot process, (ii) the telescoping of the two steps from N-[3-carbamoyl-5-ethyl-1-(2-pyridylmethyl)-1H-pyrazol-4-yl]-2-ethoxy-5- (4-ethyl-1-piperazinylsulfonyl)nicotin-amide to UK-357,903 to a single step, with the additional use of a hydroxide trapping agent to give an ambient pressure process yielding clinical quality product, and (iii) the introduction of process modifications to allow for the use of teratogenic 2-methoxyethanol, as both reagent and solvent, in the penultimate process step.

Process for the preparation of pyrazolo [4,3-d] pyrimidin-7-ones-3-pyridylsulphonyl compounds and intermediates thereof

A process is provided for the preparation of compounds of formula (I) herein comprising reacting a compound of formula (II), (III) or (IV) in the presence of -OR and a hydroxide trapping agent or in the case of compounds of formula (IV) reacting in the presence of an auxiliary base and a hydroxide trapping agent (i.e. -OR is substituted by the auxiliary base), wherein X is a leaving group and R1 to R4 are as defined above.